Figma CEO Dylan Field knows people are going to stare at his stock price. “You can’t tell people, ‘Don‘t look at the elephant ...

HII (HII), America’s largest military shipbuilder, and C3 AI (NYSE: AI), the Enterprise AI application software company, have recently announced a strategic partnership to expand digital technologies ...

A new study finds early humans ate tough grasses and tubers long before their teeth adapted, suggesting behavior, not biology, drove human evolution.

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...